Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 7Myeloid 6CNS 6Other hematologic neoplasm 3Sarcoma 2Lymphoid 2

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Meningioma 1

Interventions

Temozolomide 63Cyclophosphamide 55Radiotherapy 53Bevacizumab 50Doxorubicin 48Ifosfamide 33pazopanib 28fludarabine phosphate 28Etoposide 27Radiation 24Gemcitabine 24pembrolizumab 23Sirolimus 23Sunitinib 22Filgrastim 22Irinotecan 21Whole-Body Irradiation 20Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 20Imatinib Mesylate 20Vincristine 19Magnetic Resonance Spectroscopy 18Sorafenib 16Methotrexate 16Busulfan 16Melphalan 15Carboplatin 15Docetaxel 14Cyclosporine 14temsirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Hydroxyurea × Sarcoma × Clear all
NCT00615927 2013-03-15

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Duke University

Phase 2 Completed
64 enrolled 9 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00354913 2013-01-18

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Duke University

Phase 2 Completed
21 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Meningioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡